Multiple studies underscore the significance of m6A in renal cancer: (a) the m6A writer proteins METTL3 and METTl14 have been identified as powerful prognostic factors in ccRCC (11); (b) the m6A demethylase FTO is a synthetic lethal partner of VHL in ccRCC, and aberrant of FTO in ccRCC sensitizes these tumors to BRD9 inhibitors (12, 13); and (c) the reader protein IGF2BP3 promotes ccRCC tumor growth by stabilizing target genes in an m6A-dependent manner (14). Here, FTO is linked to nonpapillary renal cell carcinoma.